Key result
Highly selective beta-blockers like bisoprolol effectively lower blood pressure in hypertensive patients with comorbidities.
Why the study?
The review discusses the role of highly selective b-blockers, particularly bisoprolol, in blood pressure lowering therapy in comorbid patients with arterial hypertension from the standpoint of the newest European guidelines.
What is the role of highly selective beta-blockers, specifically bisoprolol, in treating patients with arterial hypertension and various comorbidities according to the 2018 European guidelines?
What is the role of highly selective beta-blockers, specifically bisoprolol, in treating patients with arterial hypertension and various comorbidities according to the 2018 European guidelines?
This review summarizes the evidence supporting the use of highly selective beta-blockers, particularly bisoprolol, in hypertensive patients with multiple comorbidities according to the 2018 European guidelines.
Answers are grounded in this paper and cite their sources.
Supports guideline-endorsed bisoprolol use in comorbid hypertension; leaves open need for updated RCTs.
The review from the standpoint of the newest European guidelines for the diagnosis and treatment of arterial hypertension discusses the role of highly selective b-blockers and, above all, the superior member of these drugs - bisoprolol in blood pressure lowering therapy in comorbid patients with arterial hypertension. In terms of evidence-based medicine, the benefits of bisoprolol in patients with comorbid coronary heart disease, chronic heart failure, atrial fibrillation, and aortic pathology are discussed. The data on the feasibility and the possibility of including in the therapy highly selective b-adrenergic blockers in patients with chronic obstructive pulmonary disease, peripheral artery disease, diabetes and sexual dysfunction are presented
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2018) conducted a review in Arterial hypertension with comorbidities. Highly selective beta-blockers (bisoprolol) was evaluated. Highly selective beta-blockers, particularly bisoprolol, are beneficial for blood pressure lowering therapy in hypertensive patients with comorbidities according to the 2018 European guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: